1. Home
  2. ALLO vs PKE Comparison

ALLO vs PKE Comparison

Compare ALLO & PKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • PKE
  • Stock Information
  • Founded
  • ALLO 2017
  • PKE 1954
  • Country
  • ALLO United States
  • PKE United States
  • Employees
  • ALLO N/A
  • PKE N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • PKE Military/Government/Technical
  • Sector
  • ALLO Health Care
  • PKE Industrials
  • Exchange
  • ALLO Nasdaq
  • PKE Nasdaq
  • Market Cap
  • ALLO 338.9M
  • PKE 285.7M
  • IPO Year
  • ALLO 2018
  • PKE N/A
  • Fundamental
  • Price
  • ALLO $1.44
  • PKE $13.36
  • Analyst Decision
  • ALLO Strong Buy
  • PKE
  • Analyst Count
  • ALLO 10
  • PKE 0
  • Target Price
  • ALLO $9.66
  • PKE N/A
  • AVG Volume (30 Days)
  • ALLO 3.3M
  • PKE 48.4K
  • Earning Date
  • ALLO 05-12-2025
  • PKE 01-14-2025
  • Dividend Yield
  • ALLO N/A
  • PKE 3.76%
  • EPS Growth
  • ALLO N/A
  • PKE N/A
  • EPS
  • ALLO N/A
  • PKE 0.36
  • Revenue
  • ALLO $22,000.00
  • PKE $61,420,000.00
  • Revenue This Year
  • ALLO N/A
  • PKE N/A
  • Revenue Next Year
  • ALLO $8.30
  • PKE N/A
  • P/E Ratio
  • ALLO N/A
  • PKE $37.41
  • Revenue Growth
  • ALLO N/A
  • PKE 15.45
  • 52 Week Low
  • ALLO $1.30
  • PKE $11.96
  • 52 Week High
  • ALLO $4.30
  • PKE $16.32
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.16
  • PKE 41.59
  • Support Level
  • ALLO $1.49
  • PKE $13.64
  • Resistance Level
  • ALLO $1.69
  • PKE $13.95
  • Average True Range (ATR)
  • ALLO 0.14
  • PKE 0.35
  • MACD
  • ALLO -0.03
  • PKE -0.01
  • Stochastic Oscillator
  • ALLO 17.50
  • PKE 19.03

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About PKE Park Aerospace Corp.

Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.

Share on Social Networks: